This Isn't Experimental: The Breast Cancer Update You Missed

Three new drugs just outperformed the 25-year breast cancer standard. Does your oncologist know? #BreastCancer #BreastCancerTreatment #SERD

👉 Get your free guide, '10 Things to Elevate Your Chemo Journey'

👉 Want personalized attention to help you along your individual cancer journey? Explore 1:1 sessions with Dr. Chaplin

👉 Want to find out more about Dr. Chaplin's journey of bringing a cancer drug to market? Explore his innovations

--------------------------------------------
Episode Description:

The drug that has been standard of care for breast cancer for nearly 25 years just got outperformed.

Not once. Three times, by three different new drugs.

And the difference between knowing about these drugs and not could change what treatment you're on right now.

A few things covered in this episode:

• Why treatment resistance in hormone positive breast cancer was always going to happen — and when
• The new mechanism that achieves nearly five times the tumor response rate of the current standard
• A liquid biopsy strategy that cuts progression risk in half — before anything shows up on a scan
• The first oral drug to beat tamoxifen in early breast cancer in 25 years

--------------------------------------------

Inquiries: 

info@elevatingcancertreatment.com

https://elevatingcancertreatment.com

--------------------------------------------

Disclaimer:
The information provided in this podcast is for educational and informational purposes only, and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have heard or read in this podcast or on this channel.
Reliance on any information provided by Dr. Jay Chaplin or Elevating Cancer Treatment is solely at your own risk. Dr. Jay Chaplin is a scientist and drug developer, not a medical doctor providing patient care. The content presented here reflects general scientific understanding and research, and may not be applicable to your individual health circumstances. Individual medical conditions and treatments vary, and no two situations are exactly alike.
Always consult with your personal healthcare provider before making any decisions about your health or treatment plan.

Transcript

SPEAKER_00 0:00

Alright, buckle up. This one is going to be long and dense, but if you or anyone you know has breast cancer, this is a really important episode for you because we're talking about not one, not two, but three new and upcoming drugs specifically for hard-to-treat breast cancers. Stick with us. Welcome to Elevating Cancer Treatment, where we cut through the noise and give you the science that actually changes outcomes. That's what you're here for, right? My background is a little different from most cancer educators. I don't just teach about oncology and options, I also design cancer drugs myself. That perspective changes everything about how I explain this very dense information, and it's why this channel exists in the first place. If that sounds like the kind of information you've been looking for, please hit like, subscribe, and ring that notification bell. And if this video helps you, please share it. Someone in your life probably needs it. I'm Dr. Jay Chaplin, I'm a PhD, not an MD. So everything here is education, not medical advice. Your oncologist is your medical team. I'm your scientific edge. So, quick note before we go further: we have a free guide called 10 Things to Elevate Your Chemo Journey. It's in the description down below. Patients tell us it reframes how they think about treatment from day one. Grab it while you're here, and if you want to work with me directly to review your treatment plan, dig into your genomics report, understand your options, that's down in the description too. So here's something your oncologist may not have told you yet. The drug that has been standard of care for mutant hormone receptor positive, HER2 negative, breast cancer, for almost 25 years, the one your treatment team may be reaching for right now, just got outperformed in a phase 3 clinical trial published in the New England Journal of Medicine. Not outperformed by a little, outperformed by a lot. A lot. And that's in patients with specific mutations, ones that develop quietly during treatment, and that most oncologists are not routinely testing for. I'm talking to you, oncologists, shame on you. Insurance covers it, and it is of amazing benefit to patients. We'll talk about that later. So, this is a new group of drugs, and it's cutting the risk of progression for metastatic breast cancer by 40 to 60% compared to the older options. And what makes this moment genuinely different, again, is that the field isn't offering one new drug after 20 plus years of stagnation. It's offering three brand new agents, each with a distinct mechanism and a distinct clinical use. They're good for different things and in different ways. And the question is now no longer just what to take, but when in your course of treatment each drug actually belongs. I'm going to break down all four of these agents mechanistically. The old, best one, an oncologist favorite, fulvestrant, and the three new ones, veptigestrant, camisestrant, and gyridestrant. I want you to understand what each one is actually doing inside a tumor cell, who belongs on which drug and when, and what that mutation in your genomic report called ESR1 actually means for your treatment options. Because right now, despite what your oncologist might think, the difference between knowing about this mutation and not knowing about it could very well be the difference between a drug that works spectacularly well and enduring side effects for one that doesn't do anything. So, again, in this episode, I'll tell you later why this ESR1 mutation almost always happens. It's not a matter of if, it's a matter of when, and why it's not bad luck. It's just biology doing exactly what it was designed to do. I'll tell you which one of these drugs just became the first oral agent to beat standard of care endocrine therapy in early breast cancer, right at the beginning. That's a setting that hasn't seen a new approved therapy in 25 years. Finally, I'll talk about how one of these drugs showed something that almost never happens in oncology trials. It didn't make the patients feel worse in order to get that better effect. So, this video is for you if you're on or being considered for endocrine therapy for estrogen receptor positive HER2-negative breast cancer at any stage. That includes patients on first-line treatment, patients who have progressed on CDK4-6 inhibitors like Ibrands, and importantly, very importantly, patients who were treated in the adjuvant setting years ago and are wondering whether current options are better than what they received and whether there's anything new to go back to. It's especially for you if you've ever seen the letters ESR1 in a liquid biopsy report or a genomic profile and had no idea what they meant for your treatment selection because they're incredibly important. So I spend a significant part of my work reading mutation reports, treatment plans, and clinical trial data for patients in these exact situations. The patterns I see are consistent. ESR1 testing is underutilized and is done far too late. Its implications are underexplained, and the treatment decisions that follow are often made without the full picture. I'm not trying to scare you. I'm trying to give you the information to avoid a pitfall many folks fall right into. I'm here to give you the biological framework to have a much sharper conversation with your oncologist. And what I'm talking about reflects the newest data. They're a little late to the game, but it's finally coming out. So let me start at the very beginning, the estrogen receptor. In hormone receptor-positive breast cancer, the estrogen receptor, it's encoded by the ESR1 gene, it acts like a molecular on-switch for tumor proliferation. Estrogen binds to it, activates it, and that goes to the nucleus and it makes the tumor grow. This is why aromatase inhibitors, which dramatically reduce estrogen production, are so effective as a first-line therapy for all of these types of cancers. But here is where the biology gets interesting and frustrating. Tumors are adaptive. They mutate quickly, they get selected for different conditions. When you cut off the estrogen supply, they don't just sit there and wait to die, they evolve. And approximately 40 to 50% of patients who progress on aromatase inhibitors plus CDK46 inhibitors will develop what are called activating ESR1 mutations. These are most commonly in the ligand binding domain of the receptor, at positions like Y537S and D538G. Those are by far the most common. What this means mechanistically is that the mutated receptor no longer needs estrogen to activate it. It turns itself on automatically and is always on, no matter what. It has essentially rewired itself around the drug that was blocking its fuel supply. Estrogen and aromatase inhibitors are now completely removed from that equation. It's not bad luck. It's just selection pressure, it's just evolution in action. You put the tumor under stress, the susceptible tumor cells all die off, but that rare cell with a mutation that lets it bypass that stress survives. It expands. And over time, that once rare cell type now dominates the tumor population, and it's totally resistant to estrogen suppression. That's why these ESR1 mutations are almost never seen at diagnosis. They're there, but they are far too rare until you block estrogen, and then they take over rapidly. You might see an ESR1 mutation at 0.1% or 0.3%, and then in months it becomes much more represented. And once again, here's the critical piece: aromatase inhibitors have no activity against these ESR1 mutant tumors. The mutation has made the receptor estrogen independent, so blocking estrogen is now irrelevant. You're getting all the side effects without any of the benefit. This is the mechanistic reason why you need a completely different class of drug, and that different class of drug is called selective estrogen receptor degraders, SERDs, SERD. For a long time we only had one of them, but now we're getting three new and vastly improved ones. Instead of blocking estrogen from binding, what a CERD does is it binds to the receptor directly and forces it into a shape that the cell's protein disposal machinery recognizes as defective or worn out. The receptor gets tagged for destruction, one way or another, and degraded, gets thrown in the trash. This happens for both regular and mutant forms of the estrogen receptor, but the ratio there depends on the particular drug. So these drugs do have far more staying power in the face of tumor evolution. And this is where our four drugs, the one old one and three new ones, diverge in mechanism and in where they operate in a patient's treatment journey. So, fulvestrin, the original SURD. Fulvestrin has been approved since 2002. That's over two decades, almost 25 years. It was the only SURD available for that time, and by that metric, it was a genuine and major advance. This drug works through an indirect mechanism. Fulvestrin binds to the estrogen receptor, it induces that conformation or shape change, and it prevents the receptor from dimerizing or linking up with another receptor, which is part of its normal activation sequence. Sort of like a car with only two wheels, it doesn't work very well, and it's a problem for the cell. This destabilizes the receptor and marks it for degradation. It puts it in the trash can of the cell. Sounds great, right? Super clean, super easy, uses the cell's own natural disposal mechanism and service to clear the receptor out, clear out the faulty machinery. Unfortunately, it's not that cut and dry. The problem is the word indirect. As we just learned, fulvestrant relies on the cell's protein disposal machinery to recognize that something's wrong and do the cleanup work. You might be surprised to learn that that process is very random and pretty inefficient. There are a particular type of PET imaging studies that can actually look inside of a cell, and they can measure estrogen receptor occupancy directly. How much is there? And they showed that even at the maximum approved dose of 500 milligrams, fulvestrin fails to achieve complete estrogen receptor suppression the way that it was designed to. The best anyone has ever measured ranges somewhere between 50% and 80% reduction. 80% is good but not great. So in ESR1 mutant tumors, where you most need this activity, fulvestrin does have some activity, but it's limited. When it's used as a comparator against these later line new drugs, fulvestrin produces a median progression-free survival of only 2.1 months with ESR1 mutant disease. Now, that's better than the aromatase inhibitors that just stop estrogen production. That's the zero month, but it isn't a satisfying result. Zero months to 2.1 months, not a big improvement. That's especially unsatisfying for a patient who has already been through other drugs like CDK4-6 inhibitors. So the bottom line on fulvestrin, it was the best available option for a very, very long time. Almost half my life. It is now the comparator arm that newer drugs beat regularly. That's not a criticism of the drug, it's a description of scientific progress. So now I want to talk with you about the ProTac Revolution. The newest drug, VEP digestrant, it was developed by our Venus, right here in Connecticut, and Pfizer. It received FDA approval in May of this year, 2026, so it's pretty new, and your oncologist may not know about it. The mechanism behind it is genuinely new to cancer therapy. It's something called a ProTAC, P-R-O-T-A-C, Proteolysis Targeting Chimera. That acronym will start appearing in your oncology notes soon, so let me explain it properly. There are a bunch of drugs coming to the market in the next decade with this format. A ProTac molecule is bifunctional. It has two ends, two binding ends. They're connected by a linker in the middle. One end binds to the target protein, in this case, the estrogen receptor. The other end binds to a cellular protein called an E3 ubiquitin ligase. I'm not going to test you on that. In this case, it's specifically a protein called cereblon. What the protac does is it forces these two proteins into physical proximity. They're held right next to each other, even though they never normally associate with each other. It handcuffs them together. The E3 ligase then does its regular job and tags the estrogen receptor with a molecule called ubiquitin. It's essentially a molecular sticky label saying dispose of me. And the receptor then is fed directly into the proteosome or the shredder of the cell and it's destroyed. Just throw that in the chipper shredder. Now, here is why this matters more than it might sound. While fulvesterin binds to the estrogen receptor and tweaks it a little bit and hopes the cell's degradation machinery kicks in, veptigesterant goes a step further. It actively recruits the degradation machinery, actively tags and labels the estrogen receptor, and directs it actively to the degradation machinery. It's the difference between putting a sticky note on a file and leaving it for someone else to take care of and physically walking over and placing it in the shredder yourself to make sure it's done. And crucially, after that receptor is destroyed, the ProTac molecule itself is released. It goes off, it's completely intact. It's undamaged by the destruction it just caused. It can go find another receptor and another cereblon molecule and go do it again. This is called catalytic degradation, and it means you need far fewer drug molecules to achieve the same or greater receptor degradation and suppression than you would with fulvestrin. Fulvestrin is a one-to-one. Fulvesterin does this by sticking permanently to the estrogen receptor. Veptigestrin doesn't. It's catalytic. Veptigestrin also degrades both wild type poorly and ESR1 mutant receptor. It's much better for the ESR mutant receptor. The mutation that defeats the aromatase inhibitors and partially resists fulvestrin, veptigestrin ignores it, it's actually better on it and degrades both forms. This idea is all well and good, but how does it stack up in the real world? We have trial results. The Veritac 2 trial. So, those were presented as a late-breaking oral presentation at ASCO back last year in 2025 and simultaneously published in the New England Journal of Medicine. As always, we've linked references down below. The trial enrolled 624 patients with estrogen receptor positive, HER2-negative, advanced breast cancer, who had progressed on those CDK4-6 inhibitors like Ibrands and combination endocrine therapy. So of those 624 patients, around half of them, 270, had confirmed ESR1 mutations. Patients were randomized one-to-one to VEP digesturin, which is a pill, orally once daily, versus fulvestrin, 500 milligram intramuscular injection. Not fun. Standard schedule. In the ESR1 mutant population, the population most resistant to aromatase inhibitors and the least affected by fulvestrin, veptigesturin produced a hazard ratio of 57, a hazard ratio of 0.57, which means a 43% reduction in risk of progression or death. It also produced an overall response rate of 19% versus only 4% for fulvestrin. That's nearly five times the tumor response rate. And it produced a clinical benefit rate of 42% versus 20% for fulvestrin. Overall, veptigesterin was a total slam dunk. Better than the previous best therapy by a long shot, and it works far better for mutant estrogen receptor molecules than the native form. That fills a very important treatment gap. And I haven't even mentioned one of the best parts yet. Again, veptigesterin is administered as a 200 milligram oral tablet, once daily with food. All oral. This is not a trivial detail for patients who have been going in to get monthly intramuscular injections. Now, as usual, there were some negative effects. The most common adverse events were fatigue, which is significant. That's 27% in the vep digesterin population versus 16% for fulvestrin. It's more potent, you do get more side effects. And there were some transaminase elevations, ALT and AST increased in the low to mid-teens percentage-wise. Importantly, though, vomiting and diarrhea, side effects that are much more prominent with fulvestrin at 15% and 24% respectively, were each present in only 6% of the patients on VEP digesterin, so that's reduced. It's mainly the fatigue that's an issue. That's also better than most of the upcoming oral SERDs we're about to talk about the next two. Since VEP digesterin is tightly focused on mutant forms of the estrogen receptor, it has fewer side effects. Because of this mild side effect profile, discontinuation rates due to toxicity in the trial were incredibly low, much lower than we normally see. Now, about that quality of life observation I mentioned earlier. Patient-reported outcomes from this Veritac 2 trial presented at ESMO ESMO conference back in 2025 showed that VEP digesterin did not produce a significant deterioration in health status or quality of life relative to baseline. In a disease setting where most progression events are preceded by significant symptom burden, that matters a lot. What else matters a lot is this drug is already approved and it's available right now. Okay, second new drug. Chemisesterin is a completely different drug operating in a completely different time window. This one doesn't wait for mutation or progression. Chemizestrin, which is being developed by AstraZeneca, is a next generation oral SERD, kind of like Veptigesterin, it's just a pill, and it's also a complete estrogen receptor antagonist. It binds and it blocks estrogen from doing anything. So it completely prevents estrogen receptor-driven transcription and also induces receptor degradation. It's a complete block, immediately and long term, including against those ESR1 mutant receptors. This is a great combination. So where chemazesterin diverges dramatically from veptigestrin and gyridestrin is not primarily in mechanism. It's in the clinical positioning, it's in the way the trial was done. Rather than treating progression, waiting for progression to happen and then treating it, it asks a different question. What if you detect the ESR1 mutation before clinical progression, when it's just a little bit, using a blood test, and then switch proactively? Honestly, this is the way we should have been doing it all along, and something I've been advocating for years. Someone finally did the right trial. Yay! So, that was the Serena 6 trial, and the results were really good. The phase 3 Serena 6 trial, NCT 04964934, enrolled patients receiving first-line aromatase inhibitor plus CDK46 inhibition who had an ESR1 mutation detected by circulating tumor DNA, that's a liquid biopsy, but had not yet experienced radiographic disease progression. So nothing had shown up on a scan, but we knew that those mutations had already happened. These patients were then randomized to either continue the current aromatase inhibitor plus CDK-4-6 inhibitor, which we knew was going to fail, or switch the aromatase inhibitor over to camisestrin while maintaining that CDK-4-6 inhibition. Not surprisingly, it worked well. The results were presented at ASCO 2025, again a year ago, in the plenary session, and simultaneously published in the New England Journal of Medicine, and they showed a 56% reduction in the risk of disease progression or death, so that's a hazard ratio of 0.44, and a median progression-free survival of approximately 16 months versus 9 months for continued aromatase inhibitor therapy. Now, that's not 16 months benefit, that's the trial was cut short. Many of those people continued for a long time. So, time to deterioration in quality of life was delayed by nearly 18 months in the camisesterin arm. The Serena 6 was the first phase 3 trial ever to demonstrate clinical utility of using circulating tumor DNA detection to guide a treatment switch ahead of disease progression. That we had to actually test this idea at all is pretty sad though. It makes so much sense. I'll speak more about that in our ASCO 2026 roundup coming out fairly soon, probably next week. This is a paradigm shift though. It's moving from reactive treatment to preemptive interception. It's about time. This means being smart instead of dumb. This means changing when the biology signals that resistance is happening before the clinical damage is visible and so that you don't have so much momentum to reverse. This is total common sense that is just very slow to make it into clinical practice. But it is finally arriving, and that's something to celebrate. So, treatment discontinuation due to adverse events in the camisesterin arm was only 1.3%. Really small. The data here are super compelling, but unfortunately it isn't approved yet, so it isn't available. The FDA pushed its decision date back to wait for more data. Boo! Boo! And it will likely be mid-2027 before it's available here in the US. However, it's already available in the United Arab Emirates, UAE, and in Saudi Arabia, because Saudi Arabia approves everything. And the EU is finalizing its approval. So, EU, you'll probably get this well before the US does. Okay, a fourth angle. This one plays in two completely different games at the same time. I want to talk about Gyridesterin. It's developed by Roche and Genentech, and I want to talk about it because it presents something that the other three drugs do not. Evidence across both late metastatic disease, including mutations, and early stage breast cancer, completely regardless of that receptor mutation status. That's really useful. So mechanistically, gyridesterin is an Oral SURD, yet another pill, and complete estrogen receptor antagonist. So this is very much like camestrin. It binds to the estrogen receptor, it promotes its degradation, and fully antagonizes both ligand-dependent and ligand-independent estrogen receptor signaling, meaning it directly addresses the ESR1 mutation-driven resistance that makes aromatase inhibitors ineffective, but it also works right from the beginning, a normal estrogen receptor. So, what sets girdesterin apart is not the mechanism. Camestesterin operates very similarly, but the breadth of the clinical evidence, which now spans two, not one, but two positive phase three trials in very different patient populations. And we're probably going to get an FDA acceptance soon. The NDA acceptance should be in 2026. Now, first trial, the phase 3 Evera trial. That's NCT 05306340. That one enrolled 373 patients, small but okay. And they all had ER-posit, HER2 negative, advanced breast cancer, and had progressed on CDK-46 inhibitors and endocrine therapy. This is the same post-CDK-4-6 setting as the Veritac 2 trial for VEP digesterin that we talked about before. Patients were randomized to Gyridesterin plus Everolemus. That's an MTOR inhibitor that we talked about in this episode. And that was against physicians' choice of endocrine therapy, one of those aromatase inhibitors or something like that, plus the Everlimus. Now, about 55% of the enrolled patients had confirmed ESR1 mutations, and the drug was specifically designed to demonstrate benefit in both the full population of everyone and the subpopulation of ESR1 mutants, that subgroup. And it did both of those easily. In the ESR-1 mutant population, the hardest to treat one, the results were really striking. Now again, median PFS, progression-free survival doesn't sound great. It was 9.99 months versus 5.45 months for the control arm. This was a very short study. 62% reduction in the risk of progression or death, so that's a hazard ratio of 0.38. That's really good. In the full population, everyone, with or without the mutation, gyridesterin plus Everlimus produced a median progression-free survival of 8.77 months versus 5.49 for the other treatment, and a 44% risk reduction. That's a hazard ratio of 0.56. All this again was presented at ESMO SMO 2025 last year, and it was the first positive head-to-head phase 3 study for an all-oral SERD-containing regimen versus a standard of care combination in this setting. Roche submitted a new drug application to the FDA in February of this year, 2026, for gyridesterin plus Everlimus in ESR1 mutated, ER-positive, HER2-negative, advanced or metastatic breast cancer following progression on prior endocrine-based regimens. Now, it's great data, but there's an important comparison note here. What sets gyridesterin apart is not the mechanism. Camesterin operates very similarly, but it's the breadth of the clinical evidence which now spans two positive phase 3 trials in very different patient populations. And an FDA NDA acceptance in 2026. We will come back to that. So, the first trial, the phase 3 Evera trial, that's NCT 05306340. It enrolled 373 patients with ER-posit, HER2 negative, advanced breast cancer. These are folks who had progressed on a CDK46 inhibitor plus endocrine therapy. That's the same post-CDK-4-6 setting as the Veritac 2 trial for VEP digestrin we talked about earlier. The patients were randomized then to gyridesterin plus Everlimus, that's an MTOR inhibitor that we talked about in this episode, versus physician's choice of endocrine therapy plus Everlimus. So that might be tamoxifen, that might be an aromatase inhibitor, we don't know. About 55% of the enrolled patients had confirmed ESR-1 mutations, and the trial was specifically designed to demonstrate benefit in both the full population and the ESR-1 mutant subgroup, and it did it easily. In the ESR-1 mutant population, the results were striking. So median progression-free survival was 10 months, 9.99, versus 5.45 months for the control arm. Those folks did continue without progression for a much longer time, but the trial was very short. There was a 62% reduction in the risk of progression or death, so that's a hazard ratio of 0.38. In the full population, everybody, regardless of mutant receptor status, Gyridestrin plus Everlimus produced a median progression-free survival of 8.77 months versus 5.49 months. That's a 44% risk reduction, or a hazard ratio of 0.56. So all of this was presented at the ESMO ESMO conference back in 2025, and it was the first positive head-to-head phase 3 study of an all-oral SERD containing regimen versus a standard of care combination for the setting. Roche submitted the new drug application to the FDA in February of this year, 2026, for Gyrideresterin plus Everlimus in that ESR-1 mutated ER-positive HER2-negative advanced or metastatic breast cancer situation for folks who had already progressed on endocrine-based regimens with CDK-4-6 inhibitors. Now, an important comparison note on this Evera trial and a point of scientific honesty. I want to be really precise here because a lot of people are comparing giridesterin to vep digesterin, and the numbers look equal or in some ways more favorable than vepdigestrin. And while that comparison is tempting, it's completely invalid. So vep digesterin was tested as a monotherapy only itself, no other drug, just that. Gyridesterin in Evera was tested in combination with Everlimus, which in and of itself is a potent antitumor drug and has very significant side effects, including immunosuppression. The comparator arms between these two were also completely different. Fulvestrin monotherapy in Veritac II, the best available drug in that group, versus for giridestrin, the weaker endocrine therapy, plus the Everlimus in the Everatrial. So these are not equivalent backdrops. This is not apples to apples or apples to oranges, this is apples to salami. But what the data does tell us is that both drugs significantly outperform their respective control arms in the ESR1 mutant disease, and that gyridestrin plus Everlimus may offer an option for patients whose disease already requires mTOR pathway cosuppression alongside ER degradation. So, cross-trial comparisons should be interpreted with serious caution. There's nothing similar about these trials. Now, the second trial for gyridesterin, the Lidera trial, this was early stage adjuvant setting. Here is where Gyridesterin does something that none of the other three drugs in this video can claim. And it's the most significant advance in early breast cancer endocrine therapy in nearly 25 years. The phase 3 Lidera trial enrolled 4,170 patients. That's a good recruitment. That's a large population. These folks had stage 1 to stage 3, ER positive, HER2 negative, early breast cancer. These are patients who had had surgery and they were set to receive adjuvant treatment to prevent recurrence. So this was the first line of systemic treatment. These patients were randomized to adjuvant gyridesterin versus standard of care endocrine therapy, so either tamoxifen or an aromatase inhibitor. This is monotherapy, new drug versus standard drug. The results, which were presented at the San Antonio Breast Cancer Symposium back in December of last year, 2025, showed a 30% reduction in risk of invasive disease recurrence or death, so that's a hazard ratio of 0.7. It also showed a 31% reduction in distant recurrence-free interval, so that's good. And 92% of the gyridesterant patients remained alive and free from invasive disease at three years, versus only 89.6 in the standard endocrine therapy group. So better, not shockingly better, but better. This was the first phase 3 trial to demonstrate that an oral SERD is superior to the standard of care adjuvant endocrine therapy in this early breast cancer setting. This is before any estrogen receptor mutations are detected. This benefit was consistent across all clinically relevant subgroups, and the safety profile showed much lower rates of treatment discontinuation than the standard endocrine therapy. That's really nice. That means that patients were tolerating gyridesterin much better than tamoxifen or aromatase inhibitors. Not worse. You've got a better drug with fewer side effects. To put this into perspective, adjuvant endocrine therapy for ER-positive early breast cancer has been tamoxifen or aromatase inhibitors for decades. Gyridesterin is the first agent to show significant superiority over both in a randomized phase 3 trial for early breast cancer. Fulvestrin is a bit better than aromatase inhibitors, it's true. But it's not better enough to convince oncologists to move up fulvestrin treatment to a first-line treatment. The improvement with gyridesterin is significantly larger. That's not a refinement, that's a potential new standard, and it's about time. Let me make this as clear as I possibly can, because the most important thing to understand is that these three new drugs are not competing against each other for the same patient at the same time. Again, they operate in different phases of the treatment journey. Fulvestrin is an intramuscular first-generation CERD. It offers incomplete receptor suppression. It has median PFS improvement of roughly two months in ESR1 mutant, metastatic disease, post-CDK4-6 inhibition. It's not great. It's better than aromatase inhibitors, but not great. It degrades estrogen receptors at a 1 to 1 ratio, and it just doesn't do a complete job. It was the standard for 20 plus years, and it's probably what your oncologist will still consider cutting edge for another 5 plus years. And it's most likely to be prescribed once aromatase inhibitors completely fail. However, it's now the weak old comparator arm that all of the newer drugs outperform. Veptigesterin is an oral protag. It's a pill. It induces catalytic ER degradation through that E3 ubiquitin ligase recruitment, and it's far more potent. It's already FDA approved, and it's indicated as a monotherapy for ESR1 mutated, estrogen receptor positive, HER2-negative, advanced or metastatic breast cancer after at least one prior line of endocrine therapy. Tamoxifen, aromatase inhibitor, it doesn't matter. Veptigesterin more than doubles progression-free survival versus fulvestrin, the previous best, especially in ESR1 mutant disease. And since it's designed to work on mutant estrogen receptors primarily, it wouldn't work well in early disease, but it has a pretty good safety profile, low side effects. It's available right now, it's fully approved. Camisesterin, number two, it's also a pill, it's an oral SERD, it's a complete ER antagonist. It's not yet FDA approved, and it operates on a different clock. This one is first line, CTA-guided preemptive switching in combination with CDK4-6 inhibition. This is before clinical progression. You don't wait for failure. You see the mutation, you switch. It's designed for patients who are still on first-line therapy whose liquid biopsy detects an emerging ESR1 mutation. It works really well. Unfortunately, camisestrin isn't approved yet. Ooh, FDA, and the application has yet to be resubmitted. You'll be able to get it soon, probably in a year to a year and a half, but not now unless you're in the UAE or Saudi Arabia. Gyridesterin, number three, is an oral SERD, again, and it's a complete estrogen receptor blocker, like camizestrin. It's also not yet FDA approved. The new drug application has been accepted, but the deadline for review is December of this year, 2026. It operates in two distinct settings. In the post-CDK4-6 metastatic setting, it's being developed in combination with Everolemus for ESR1 mutant disease. In the adjuvant setting, it's the first oral SERD to demonstrate superiority over tamoxifen and aromatase inhibitors in an early stage phase 3 trial. That's a setting that the other three drugs in this video have not been able to break into. So if someone asks you which drug is best, that question doesn't have one answer. It has four answers, and the right one depends entirely on where you are in your treatment journey and whether your tumor has an ESR1 mutation. And most importantly, what your oncologist is trying to achieve from what they know. The practical question for you is: do you know what your ESR1 mutation status is? Has anyone ordered a liquid biopsy or a cell-free DNA test during your treatment? There's a video on that that we did quite some time ago. This is how ESR1 mutations are detected, and they develop before or in the early days of therapy, not way at the end at the diagnosis of reoccurrence, despite what your oncologist may believe. Look, Mount Everest didn't just appear when it was discovered. It was there all along. Same thing here. If you've been on an aromatase inhibitor plus a CDK4-6 inhibitor, the 40 to 50% mutation risk means that there's a real probability, a coin flip, that you have developed one, and it has probably been there for over a year, growing in percentage, taking over, and leading you toward treatment failure. Ask for the test. Ask specifically. Have I been tested for ESR1 mutations? If not, why not? So I want to address something directly because I see this pattern consistently. Oncology practice moves on a long delay. A drug will receive approval. The trial behind it is published in a major journal, very accessible, and it still takes 12 to 24 months, honestly often longer, up to five years, for that change to consistently reach clinical practice. This is not intentional negligence. It's the reality of a very busy specialty with many patients to see and limited time to read every trial, and update on the newest NCCN guidelines. But here's the consequence. A patient whose ESR1 mutation status is unknown because your oncologist thinks that they don't need to test for it, those patients cannot be appropriately matched to the new drugs designed specifically for that situation. A patient still on fulvestrin with an ESR-1 mutant disease when VEP digesterin is now FDA approved for that exact setting, that patient is getting a significantly less effective treatment. Please don't let it be you. And a patient on aromatase inhibitors plus CDK-4-6 inhibition, a patient for whom chamestestrin's Serena 6 data could be directly relevant, is directly relevant, may not even know that a CTDNA monitoring strategy exists, that those mutations are important, or that they can ask for this. This is exactly the kind of gap my consulting clients come to me about. They've been on treatment for months and no one has mentioned ESR1 testing, and when we finally look at the genomic picture together, the options can change significantly. Folks who want the best possible treatment need the best data. If you want that kind of individualized analysis of your situation, the link to work with me is down below in the description. There's also a major conceptual confusion here worth naming, because fulvestrin, veptigestrin, camizestrin, and gyridestrin all carry the label of CERD. And some patients, and sadly most providers, assume that because they're all in the same class with essentially similar names, that they're all approximately equivalent. It's true, the mechanism and the names overlap. But the pharmacokinetics, how fast it works and how it works, the receptor occupancy data, how you dose them, the mechanism of receptor clearance, and now four phase three trials all say that they're very different drugs. Being in the same class does not mean being the same drug, just like a Volkswagen is not the same as a Lamborghini. Yes, they're both cars, but they're four very different scenarios. So before I close, I want to be very precise about something, because nuance matters here a lot. What this all means for you, if you have breast cancer, practically, is that there's a conversation for you to initiate with your treatment team. Don't let them make the decisions unilaterally. You need to be the one who initiates it because the data is recent. Four phase three trials across multiple treatment settings just landed in the same calendar year. And the awareness gap is very big and very real. The standard of care for hormone-positive HER2-negative breast cancer, even at a very early stage, is being completely rewritten right now. We have a new class of drugs, the ProTac Estrogen Receptor Degraders, and we've got one FDA approved right now for ESR1 mutant metastatic disease. We've got a CT DNA guided interception strategy, finally, that is having the risk of progression in first-line patients when a mutation is detected, so get that test. An oral SERD just significantly beat tamoxifen and aromatase inhibitors in early breast cancer for the first time in 25 years. All of these independently are amazing. One of those is approved, and one of them has a decision date by Christmas. The other one shouldn't be too far behind it. So you now understand why ESR1 mutations happen, what they mean across the full treatment timeline, and what to ask in terms of testing. If this was useful, please hit like, subscribe if you want to stay ahead of the data and not behind it, and please share this with someone who's navigating hormone-positive breast cancer. Their treatment may not be the best that it could be. Save somebody's life. Please also leave me a comment down below. Has your oncologist discussed early ESR1 testing with you? Or how did they respond when you asked them for early testing? If you want to understand how to think about a genomic report and how to interpret those mutation allele fractions and what different mutations can mean, and how that should inform your treatment plans and decisions, please watch this next video right here. This channel exists to empower you to make thoughtful, biologically grounded decisions. That is your best possible leverage.